- Two oral presentations of phase 2 study findings from novel treatment options: an all-oral decitabine-cedazuridine combination for AML and zipalertinib for NSCLC that harbors exon 20 insertion mutations
- Additional presentations to include real-world data on the safety and effectiveness of two approved regimens: trifluridine-tipiracil paired with bevacizumab for metastatic colorectal cancer and futibatinib for cholangiocarcinoma
PRINCETON, N.J., April 23, 2025 -- Taiho Oncology, Inc., a company developing and commercializing novel treatments for hematologic malignancies and solid tumors, announced today that it will present new data from five studies, including two oral presentations, at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held May 30 through June 3 at McCormick Place in Chicago.
The oral presentations will feature data regarding ASTX727 (oral decitabine-cedazuridine), an agent approved for myelodysplastic syndromes (MDS), paired with venetoclax for the treatment of acute myeloid leukemia (AML) and the novel investigational drug candidate zipalertinib for the treatment of non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion mutations.
The company will also share data on three real-world studies of two FDA-approved therapies: trifluridine and tipiracil paired with bevacizumab for the later-line treatment of adult patients with metastatic colorectal cancer and futibatinib for the treatment of adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma.
"ASCO provides an invaluable opportunity to bring together the leading minds in oncology and discuss emerging new therapies and our understanding of real-world outcomes of existing therapies," said Harold Keer, MD, PhD, Chief Medical Officer, Taiho Oncology. "Our data at ASCO will continue to demonstrate our unwavering commitment to meaningful innovation that can potentially improve the lives of patients with cancer, their families and their caregivers."
Details about these presentations can be found below:
Oral Presentations
Title: Efficacy of zipalertinib in NSCLC patients with EGFR exon 20 insertion mutations who received prior platinum-based chemotherapy with or without amivantamab
Abstract Number: 8503
Session Name: Lung Cancer – Non-Small Cell Metastatic
Session Type: Oral Abstract Session
Session Date: June 1, 2025
Presentation Time: 8 a.m. – 11 a.m. CDT
Location: Arie Crown Theater | Live Stream
Presenter: Helena A. Yu, MD, Memorial Sloan Kettering Cancer Center
Title: An all-oral regimen of decitabine-cedazuridine (DEC-C) plus venetoclax (VEN) in patients (pts) with newly diagnosed acute myeloid leukemia (AML) ineligible for intensive induction chemotherapy: Results from a Phase 2 cohort of 101 pts
Abstract Number: 6504
Session Name: Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Session Type: Oral Abstract Session
Session Date: June 2, 2025
Presentation Time: 3 p.m. – 6 p.m. CDT
Location: S100a | Live Stream
Presenter: Amer Zeidan, MBBS, Yale Cancer Center
Poster Presentation
Title: Real-world treatment patterns and outcomes with trifluridine/tipiracil monotherapy or in combination with bevacizumab in metastatic colorectal cancer
Abstract Number: 3580
Session Name: Gastrointestinal Cancer—Colorectal and Anal
Session Type: Poster Presentation
Session Date: May 31, 2025
Presentation Time: 9 a.m. – 12 p.m. CDT
Location: Hall A - Posters and Exhibits | On Demand
Presenter: Donald Richards, MD, PhD, of Texas Oncology
Online Abstracts
Title: Real-world Clinical Outcomes of Patients with Metastatic Colorectal Cancer (mCRC) Treated with Trifluridine-Tipiracil + Bevacizumab by Performance Status
Abstract Number: E15606
Session Type: Publication Only
Publication Date: May 22, 2025
Publication Time: 5 p.m. EDT
Lead Author: Maliha Nusrat, MD, MS, Memorial Sloan Kettering Cancer Center
Title: Real-World patient characteristics and treatment patterns among cholangiocarcinoma patients treated with FGFR inhibitors
Abstract Number: E16262
Session Type: Publication Only
Publication Date: May 22, 2025
Publication Time: 5 p.m. EDT
Lead Author: Amit Mahipal, MD, University Hospitals Seidman Cancer Center and Case Comprehensive Cancer Center
About Taiho Oncology, Inc.
The mission of Taiho Oncology, Inc. is to improve the lives of patients with cancer, their families and their caregivers. The company specializes in the development and commercialization of orally administered anti-cancer agents for various tumor types. Taiho Oncology has a robust pipeline of small-molecule clinical candidates targeting solid-tumor and hematological malignancies, with additional candidates in pre-clinical development. Taiho Oncology is a subsidiary of Taiho Pharmaceutical Co., Ltd. which is part of Otsuka Holdings Co., Ltd. Taiho Oncology is headquartered in Princeton, New Jersey and oversees its parent company's European and Canadian operations, which are located in Baar, Switzerland and Oakville, Ontario, Canada.
For more information, visit https://www.taihooncology.com/, and follow us on LinkedIn and X.
Taiho Oncology and the Taiho Oncology logo are registered trademarks of Otsuka Holdings Co., Ltd. or its subsidiaries.
Taiho Oncology
This News is brought to you by Qube Mark, your trusted source for the latest updates and insights in marketing technology. Stay tuned for more groundbreaking innovations in the world of technology.
